Agios Pharmaceuticals, Inc. Forecasted to Earn FY2027 Earnings of ($3.21) Per Share (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIOFree Report) – Equities research analysts at Leerink Partnrs issued their FY2027 EPS estimates for Agios Pharmaceuticals in a note issued to investors on Monday, June 3rd. Leerink Partnrs analyst A. Berens anticipates that the biopharmaceutical company will post earnings per share of ($3.21) for the year. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($5.57) per share.

Agios Pharmaceuticals (NASDAQ:AGIOGet Free Report) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.20. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 41.41%. The company had revenue of $8.19 million during the quarter, compared to analyst estimates of $8.37 million. During the same quarter last year, the business posted ($1.47) EPS. The company’s revenue for the quarter was up 46.0% on a year-over-year basis.

Several other equities research analysts have also issued reports on the company. The Goldman Sachs Group lifted their price target on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a report on Tuesday. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 29th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, April 9th. Royal Bank of Canada lifted their price objective on shares of Agios Pharmaceuticals from $44.00 to $53.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. lowered their target price on shares of Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating on the stock in a research report on Friday, February 23rd. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $45.33.

Get Our Latest Research Report on Agios Pharmaceuticals

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $47.80 on Thursday. Agios Pharmaceuticals has a one year low of $19.80 and a one year high of $49.06. The business’s 50-day moving average price is $32.84 and its two-hundred day moving average price is $27.95. The company has a market capitalization of $2.71 billion, a P/E ratio of -7.56 and a beta of 0.77.

Insider Buying and Selling

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,791 shares of the company’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total transaction of $214,642.05. Following the completion of the sale, the director now directly owns 137,396 shares in the company, valued at $3,785,259.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AGIO. Farallon Capital Management LLC raised its stake in Agios Pharmaceuticals by 34.1% during the 1st quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company’s stock valued at $163,469,000 after purchasing an additional 1,423,000 shares during the last quarter. Tidal Investments LLC acquired a new position in shares of Agios Pharmaceuticals during the first quarter valued at about $946,000. Kennedy Capital Management LLC acquired a new position in shares of Agios Pharmaceuticals during the first quarter valued at about $4,658,000. Caxton Associates LP bought a new stake in shares of Agios Pharmaceuticals in the first quarter valued at about $1,087,000. Finally, Price T Rowe Associates Inc. MD grew its position in Agios Pharmaceuticals by 23.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after buying an additional 388,381 shares in the last quarter.

Agios Pharmaceuticals Company Profile

(Get Free Report)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

Recommended Stories

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.